Lenalidomide

證據等級: L5

預測適應症: 6 個

Lenalidomide: From Multiple Myeloma / MDS to Myeloid Leukemia

One-Sentence Summary

Lenalidomide (Revlimid®) is an oral immunomodulatory drug (IMiD) approved globally for multiple myeloma and myelodysplastic syndromes (MDS) with del(5q) cytogenetic abnormality. The TxGNN model predicts it may be effective for Myeloid Leukemia (including AML and high-risk MDS), with 50 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Multiple myeloma; MDS with del(5q)-associated transfusion-dependent anemia (based on global approvals)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.49%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Lenalidomide is a member of the immunomodulatory drugs (IMiDs) class, derived from thalidomide. It exerts its anticancer effects primarily through binding to cereblon (CRBN), an E3 ubiquitin ligase substrate receptor. This interaction recruits and promotes the degradation of key transcription factors — IKZF1 (Ikaros) and IKZF3 (Aiolos) — that are critical survival factors in malignant hematopoietic cells. Beyond this targeted mechanism, lenalidomide also activates T cells and natural killer (NK) cells, inhibits angiogenesis, and promotes apoptosis in abnormal clones.

Myeloid leukemia (including AML) and MDS share a common origin in hematopoietic stem cell dysregulation. MDS is a recognized pre-leukemic state — approximately one-third of patients progress to AML. Lenalidomide’s established activity in del(5q) MDS reflects its ability to suppress clonal hematopoiesis by selectively eliminating del(5q) clones via CDC20B-CK1α-mediated degradation, while restoring normal erythropoiesis. The same molecular vulnerabilities — chromosome 5 deletions, aberrant epigenetic regulation, impaired NK-cell immune surveillance, and dysregulated IKZF1 activity — are present across the myeloid leukemia disease continuum.

The TxGNN prediction is consistent with a large body of translational and clinical evidence. Lenalidomide has been investigated across the full spectrum of myeloid disease: as monotherapy and combined with azacitidine in high-risk MDS and AML, as combination chemotherapy (MEC regimen, idarubicin + cytarabine) in relapsed/refractory AML, and as post-transplant maintenance therapy to prevent relapse. A 2025 mechanistic study (PMID 39881283) confirmed that the histone demethylase KDM5C stabilizes CRBN in AML cells, directly linking lenalidomide’s known mechanism to leukemia cell biology.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01029262	Phase 3	Completed	239	Lenalidomide vs. placebo in transfusion-dependent, lower-risk MDS without del(5q), refractory to ESA
NCT00843882	Phase 3	Active, Not Recruiting	247	Lenalidomide alone vs. with epoetin alfa in low/int-1 risk MDS with symptomatic anemia
NCT01522976	Phase 2/3	Active, Not Recruiting	282	Azacitidine ± lenalidomide or vorinostat for higher-risk MDS and CMML
NCT01358734	Phase 2	Completed	88	Lenalidomide vs. AZA vs. AZA + lenalidomide for newly diagnosed AML in patients ≥65 years
NCT01743859	Phase 2	Completed	37	Sequential azacitidine + lenalidomide for relapsed/refractory AML and high-risk MDS
NCT03118466	Phase 2	Completed	41	MEC chemotherapy + lenalidomide for relapsed or refractory AML
NCT00957385	Phase 2	Completed	24	Lenalidomide maintenance in AML patients ≥60 years (CR1) or <60 years (CR2+)
NCT00065156	Phase 2	Completed	148	Landmark trial: lenalidomide monotherapy in transfusion-dependent MDS with del(5q)
NCT02472691	Phase 2	Completed	50	Azacitidine + lenalidomide + donor lymphocyte infusions for MDS/CMML/AML relapse post-allo-SCT
NCT00360672	Phase 2	Completed	27	Lenalidomide in relapsed/refractory AML or high-risk MDS with chromosome 5 abnormalities

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30271212	2018	Meta-analysis	Cancer Manag Res	Systematic review and meta-analysis of lenalidomide efficacy and safety specifically in AML
31221030	2019	Meta-analysis	Hematology	Meta-analysis of azacitidine + lenalidomide for AML, MDS, and CMML — efficacy and adverse events
37288607	2023	Review	Am J Hematol	MDS 2023 update: diagnosis, risk stratification, and management including lenalidomide role
37874917	2023	Review	Blood	Clinical decision-making in MDS; risk-benefit framework for lenalidomide in lower-risk disease
23644421	2013	Review	Leukemia	AZA + lenalidomide combination in MDS and AML — mechanistic rationale and clinical evidence
23316859	2013	Review	Expert Opin Investig Drugs	Lenalidomide as a novel treatment for AML: mechanism, completed trials, and future perspectives
37259567	2023	Prospective study	Haematologica	Azalena-Trial: AZA + lenalidomide + DLI for post-transplant relapse of AML, MDS, and CMML
37435080	2023	Prospective study	Front Immunol	AZA + low-dose lenalidomide as relapse prophylaxis maintenance after allo-HSCT in AML
39881283	2025	Basic science	Cell Mol Biol Lett	KDM5C stabilizes CRBN to enhance lenalidomide sensitivity in AML cells — key mechanistic insight
35512188	2022	Cohort study	Blood	Lenalidomide exposure selectively promotes TP53-mutated therapy-related myeloid neoplasms — safety signal

India Market Information

Lenalidomide is not registered or marketed in India. No product licenses were found in the regulatory database (0 registrations).

For reference, lenalidomide (Revlimid®) holds approval from the US FDA for multiple myeloma, del(5q) MDS, mantle cell lymphoma, and follicular/marginal zone lymphoma, and from the EMA under comparable indications. Access for Indian patients would require import under specific regulatory pathways, compassionate use programs, or enrollment in clinical trials.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunomodulatory drug (IMiD) — not conventional cytotoxic; antineoplastic via CRBN-mediated protein degradation
Myelosuppression Risk	High — neutropenia and thrombocytopenia are very common adverse effects; Black Box Warning for myelosuppression; requires dose modification and growth factor support
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (weekly for first 8 weeks, then monthly); serum creatinine / CrCl (mandatory dose adjustment for renal impairment); thyroid function; DVT/PE signs and symptoms
Handling Protection	Oral capsule — standard oral antineoplastic precautions apply; REMS program enrollment is mandatory (due to severe teratogenicity risk analogous to thalidomide); strict pregnancy prevention program required for all patients

Safety Considerations

Drug Interactions: 347 total interactions identified in the DDI database. Key interactions include:

Major severity: Rosuvastatin, Simvastatin — risk of increased statin plasma concentrations; consider dose reduction or switch to a less interactive statin
Moderate severity: Eliglustat, Naltrexone — monitor for pharmacodynamic or pharmacokinetic changes
Unknown severity (clinical significance to be evaluated): Metformin, Prednisone, Omeprazole, Lansoprazole, Pantoprazole, Vancomycin, Morphine, Doxycycline, Clotrimazole, Rosiglitazone, and others

Detailed warnings and contraindications were not available in the current Evidence Pack. Please refer to the US FDA-approved package insert (Revlimid®) for complete safety information. Known Black Box Warnings include: myelosuppression, deep vein thrombosis/pulmonary embolism (especially when combined with dexamethasone), and embryo-fetal toxicity (absolute contraindication in pregnancy).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Lenalidomide has robust clinical evidence in myeloid malignancies — including a completed Phase 3 trial in MDS and multiple completed Phase 2 trials across the AML/MDS spectrum — supported by two meta-analyses confirming measurable efficacy signals. The TxGNN score of 99.49% is biologically justified given the direct mechanistic overlap between MDS (original indication) and myeloid leukemia. However, the drug is not registered in India, safety data gaps remain in this Evidence Pack, and the evidence in AML specifically is less definitive than in MDS.

To proceed, the following is needed:

Regulatory pathway: Establish an India access pathway for a currently unregistered drug (import license, compassionate use, or clinical trial IND)
Safety documentation: Retrieve the complete package insert warnings and contraindications (currently data gap); implement a teratogenicity risk management program equivalent to Revlimid REMS®
Subgroup stratification: Clarify the target patient population — del(5q) MDS, non-del(5q) MDS, or AML — as response rates and regulatory status differ substantially by subgroup
Myelosuppression management plan: CBC monitoring protocol (weekly for ≥8 weeks), dose-modification guidelines, and G-CSF/PLT transfusion thresholds
DVT/PE prophylaxis protocol: Risk-stratified anticoagulation or aspirin regimen, especially if combined with dexamethasone or other agents
Renal function assessment: Mandatory CrCl-based dose adjustment protocol for all enrolled patients
TP53 mutation screening: In light of PMID 35512188, pre-screening for existing TP53 clonal hematopoiesis may be advisable to avoid accelerating therapy-related myeloid neoplasms
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.